Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-EBV CAR T cells BRG01

A preparation of autologous T lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) targeting an Epstein-Barr virus (EBV) protein, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous anti-EBV CAR T cells BRG01 targets a specific EBV protein expressed on EBV-positive cancer cells and promotes killing of these cancer cells. EBV infection is associated with various cancers and the expression of certain EBV specific proteins plays a key role in tumor cell proliferation and survival.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous anti-EBV CAR-T cells BRG01
Code name:	BRG 01 BRG-01 BRG01

autologous anti-EBV CAR T cells BRG01

Search NCI's Drug Dictionary